Understanding the Biochemical Basis of Alzheimer's Disease: A Clinical Chemistry Approach
Keywords:
Alzheimer's Disease, Biochemical Mechanisms, Clinical Chemistry, Biomarkers, Neurodegeneration, Therapeutic Interventions.
Abstract
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline and memory loss. This study explores the biochemical underpinnings of AD through a clinical chemistry lens, focusing on the alterations in key biomolecules and metabolic pathways associated with the disease. We examine the roles of amyloid-beta peptides, tau protein hyperphosphorylation, and oxidative stress in neuronal damage, alongside their implications for early diagnosis and therapeutic interventions. By analyzing biomarkers in cerebrospinal fluid and plasma, we aim to enhance the understanding of disease mechanisms and improve diagnostic accuracy. Additionally, this approach highlights the potential of targeted therapies that address specific biochemical pathways, paving the way for more effective treatment strategies. Through a comprehensive review of current literature and ongoing research, this study seeks to contribute to the growing body of knowledge surrounding AD and its biochemical foundations, ultimately aiming to facilitate advancements in clinical practice and patient care.
References
[1] S. C. Curtin, B. A. Tejada-Vera, and B. A. Bastian, "Deaths: leading causes for 2020," cdc.gov, 2023. [Online]. Available: https://cdc.gov
[2] M. Heron, "Deaths: leading causes for 2019," cdc.gov, 2021. [Online]. Available: https://cdc.gov
[3] C. S. Liang et al., "Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis," The Lancet Healthy Longevity, vol. 2, no. 8, pp. e479-e488, 2021. [Online]. Available: https://thelancet.com
[4] M. B. Abubakar et al., "Alzheimer’s disease: an update and insights into pathophysiology," Frontiers in Aging Neuroscience, vol. 14, p. 742408, 2022. [Online]. Available: https://frontiersin.org
[5] Rahman, Z. Banu, R. Rani, and R. Mehdiya, "Unravelling Alzheimer’s disease: Insights into pathophysiology, etiology, diagnostic approaches, and the promise of aducanumab, lecanemab, and donanemab," Journal of Phytonanotechnology and Pharmaceutical Sciences, vol. 4, no. 3, pp. 1-10, 2024. [Online]. Available: https://researchgate.net
[6] Crestini et al., "Prions and neurodegenerative diseases: a focus on Alzheimer’s disease," Journal of Alzheimer's Disease, vol. 85, no. 2, pp. 503-518, 2022. [Online]. Available: https://escholarship.org
[7] N. Pathak et al., "Neurodegenerative disorders of Alzheimer, Parkinsonism, amyotrophic lateral sclerosis and multiple sclerosis: an early diagnostic approach for precision treatment," Metabolic Brain Disease, pp. 1-38, 2021. [Online]. Available: [HTML].
[8] V. Litvinenko and V. Y. Lobzin, "On a New Paradigm of the Development of Neurodegenerative Diseases by the Example of Alzheimer's Disease and Parkinson's Disease," Advances in Gerontology, 2022. [Online]. Available: https://springer.com
[9] X. Zhao et al., "Mesenchymal stem cell therapies for Alzheimer's disease: preclinical studies," Metabolic Brain Disease, 2021. [Online]. Available: [HTML].
[10] A. King, I. Bodi, and C. Troakes, "The neuropathological diagnosis of Alzheimer's disease—the challenges of pathological mimics and concomitant pathology," Brain Sciences, 2020. [Online]. Available: https://mdpi.com
[11] F. J. Hart de Ruyter et al., "Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases," Acta Neuropathologica, vol. 148, no. 1, p. 24, 2024. [Online]. Available: https://springer.com
[12] P. Sánchez-Juan et al., "Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles," Brain, vol. 147, no. 5, pp. 1667-1679, 2024. [Online]. Available: https://oup.com
[13] A. D. Henriques et al., "Genome-wide profiling and predicted significance of post-mortem brain microRNA in Alzheimer’s disease," Mechanisms of Ageing and Development, vol. 191, p. 111352, 2020. [Online]. Available: [HTML].
[14] X. Yin et al., "The role of amyloid-beta and tau in the early pathogenesis of Alzheimer’s Disease," Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, vol. 27, p. e933084-1, 2021. [Online]. Available: https://nih.gov
[15] H. Zhang et al., "Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease," International Journal of Biological Sciences, vol. 17, no. 9, p. 2181, 2021. [Online]. Available: https://nih.gov
[16] A. R. Roda et al., "Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease," Neural Regeneration Research, vol. 17, no. 8, pp. 1666-1674, 2022. [Online]. Available: https://lww.com
[17] S. Muralidar et al., "Role of tau protein in Alzheimer's disease: The prime pathological player," International Journal of Biological Macromolecules, vol. 163, pp. 1599-1617, 2020. [Online]. Available: https://academia.edu
[18] Lateef, D., Nasser, N., and Mohsein, O., "The relationships between Apelin, Vaspin and thyroid hormone levels in obese diabetic and non-diabetic women," Journal of Experimental and Clinical Medicine, vol. 41, no. 2, pp. 239-245, 2024.
[19] Y. H. Guan et al., "The role of microglia in Alzheimer's disease and progress of treatment," Ibrain, vol. 8, no. 1, pp. 37-47, 2022. [Online]. Available: https://wiley.com
[20] Y. Cai et al., "Microglia in the neuroinflammatory pathogenesis of Alzheimer's disease and related therapeutic targets," Frontiers in Immunology, 2022. [Online]. Available: https://frontiersin.org
[21] Z. Du, M. Li, J. Ren, and X. Qu, "Current strategies for modulating Aβ aggregation with multifunctional agents," Accounts of Chemical Research, 2021. [Online]. Available: [HTML].
[22] Q. Shi, R. A. Gutierrez, and M. A. Bhat, "Microglia, Trem2, and Neurodegeneration," The Neuroscientist, 2024. [Online]. Available: https://sagepub.com
[23] Faisal, A. N., Abbas, A. M., and Mohsein, O. A., "Histological and cytokine-based biomarkers in the early diagnosis of cancer," Indonesian Journal on Health Science and Medicine, vol. 2, no. 2, pp. 10-21070, 2025.
[24] M. Abbas, "Potential role of nanoparticles in treating the accumulation of amyloid-beta peptide in Alzheimer's patients," Polymers, 2021. [Online]. Available: https://mdpi.com
[25] J. Gupta, R. Gupta, and P. Sharma, "Alzheimer’s Disease: Role of Amyloid-β Peptide in the Pathogenesis of Neurodisorder," European Journal of Molecular & Clinical Medicine, vol. 9, no. 7, pp. 7282-7290, 2022. [Online]. Available: https://researchgate.net
[26] M. Inyushin, A. Zayas-Santiago, L. Rojas, and L. Kucheryavykh, "On the role of platelet-generated amyloid beta peptides in certain amyloidosis health complications," Frontiers in Immunology, vol. 11, p. 571083, 2020. [Online]. Available: https://frontiersin.org
[27] M. K. Rasmussen, H. Mestre, and M. Nedergaard, "Fluid transport in the brain," Physiological Reviews, vol. 102, no. 2, pp. 1025-1151, 2022. [Online]. Available: https://physiology.org
[28] A. Al-Mekhlafi et al., "Elevated free phosphatidylcholine levels in cerebrospinal fluid distinguish bacterial from viral CNS infections," Cells, vol. 10, no. 5, p. 1115, 2021. [Online]. Available: https://mdpi.com
[29] Adnan, A., Farhan, Z. M., and Mohsein, O. A., "Understanding the link between diabetes mellitus and fatty liver disease: A narrative review," Int. J. Chem. Stud., vol. 12, no. 4, pp. 40-48, 2024.
[30] M. Blomqvist, H. Zetterberg, K. Blennow, and J. E. Månsson, "Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration," Molecular and Cellular Neuroscience, vol. 116, p. 103670, 2021. [Online]. Available: https://sciencedirect.com
[31] A. Varesi et al., "Blood-based biomarkers for Alzheimer’s disease diagnosis and progression: an overview," Cells, vol. 11, no. 8, p. 1367, 2022. [Online]. Available: https://mdpi.com
[32] S. Mankhong et al., "Development of Alzheimer’s disease biomarkers: From CSF-to blood-based biomarkers," Biomedicines, vol. 10, no. 4, p. 850, 2022. [Online]. Available: https://mdpi.com
[33] S. P. Padala and P. A. Newhouse, "Blood-based biomarkers in Alzheimer's disease: A mini-review," Metabolic Brain Disease, 2023. [Online]. Available: https://nih.gov
[34] Abdulmuttaleb, N. A., Mohammed, M. Q., and Mohsein, O. A., "Exploring the connection between inflammatory cytokines, hypertension, and diabetes in angina patients," Cytokines, vol. 14, no. 15, p. 16, 2024.
[35] S. Lista et al., "A critical appraisal of blood-based biomarkers for Alzheimer’s disease," Ageing Research Reviews, p. 102290, 2024. [Online]. Available: [HTML].
[36] H. Hampel et al., "The amyloid-β pathway in Alzheimer’s disease," Molecular Psychiatry, vol. 26, no. 10, pp. 5481-5503, 2021. [Online]. Available: https://nature.com
[37] M. Seuma, B. Lehner, and B. Bolognesi, "An atlas of amyloid aggregation: the impact of substitutions, insertions, deletions and truncations on amyloid beta fibril nucleation," Nature Communications, 2022. [Online]. Available: https://nature.com
[38] Abbas, A. M., Shewael, I. H., and Mohsein, O. A., "Lipoprotein ratios as biomarkers for assessing chronic atherosclerosis progression," Academia Open, vol. 10, no. 1, pp. 10-21070, 2025.
[39] R. Fernández-Calle et al., "APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases," Molecular Neurodegeneration, vol. 17, no. 1, p. 62, 2022. [Online]. Available: https://springer.com
[40] X. Zhou, A. K. Y. Fu, and N. Y. Ip, "APOE signaling in neurodegenerative diseases: an integrative approach targeting APOE coding and noncoding variants for disease intervention," Current Opinion in Neurobiology, 2021. [Online]. Available: https://sciencedirect.com
[41] S. Parhizkar and D. M. Holtzman, "APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease," Seminars in Immunology, 2022. [Online]. Available: https://sciencedirect.com
[42] J. Goldman et al., "Predictive testing for neurodegenerative diseases in the age of next-generation sequencing," Journal of Genetic Counseling, vol. 30, no. 2, pp. 553-562, 2021. [Online]. Available: https://wiley.com
[43] M. Zhao et al., "A study of the SORL1 gene in the pathogenesis of late-onset Alzheimer’s disease by affecting the expression of BDNF," Research Square, 2021. [Online]. Available: https://researchsquare.com
[44] K. Barthelson et al., "… analysis reveals subtle effects on mitochondrial function and iron homeostasis of mutations in the SORL1 gene implicated in early onset familial Alzheimer's disease," Molecular Brain, 2020. [Online]. Available: https://springer.com
[45] Abbas, Z. K., et al., "Immunological biomarkers and their role in the diagnosis and prognosis of leishmaniasis: A case–control study," Tropical Parasitology, vol. 15, no. 1, pp. 33-41, 2025.
[46] C. Y. Chen et al., "Endophenotypic effects of the SORL1 variant rs2298813 on regional brain volume in patients with late-onset Alzheimer’s disease," Frontiers in Aging Neuroscience, vol. 14, p. 885090, 2022. [Online]. Available: https://frontiersin.org
[47] M. M. Rahman and C. Lendel, "Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology," Molecular Neurodegeneration, 2021. [Online]. Available: https://springer.com
[48] S. Srivastava, R. Ahmad, and S. K. Khare, "Alzheimer’s disease and its treatment by different approaches: A review," European Journal of Medicinal Chemistry, vol. 216, p. 113320, 2021. [Online]. Available: [HTML]
[49] U. Ganguly et al., "Oxidative stress, neuroinflammation, and NADPH oxidase: implications in the pathogenesis and treatment of Alzheimer’s disease," Oxidative Medicine and Cellular Longevity, vol. 2021, p. 7086512, 2021. [Online]. Available: https://wiley.com
[50] K. D. Anapindi et al., "Mass spectrometry approaches empowering neuropeptide discovery and therapeutics," Pharmacological Reviews, vol. 74, no. 3, pp. 662-679, 2022. [Online]. Available: https://nih.gov
[51] C. S. Sauer et al., "Developing mass spectrometry for the quantitative analysis of neuropeptides," Expert Review of Proteomics, vol. 18, no. 7, pp. 607-621, 2021. [Online]. Available: https://nih.gov
[52] J. Li and X. Zhan, "Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas," Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, vol. 1869, no. 3, p. 140584, 2021. [Online]. Available: [HTML]
[53] N. Li, D. M. Desiderio, and X. Zhan, "The use of mass spectrometry in a proteome-centered multiomics study of human pituitary adenomas," Mass Spectrometry Reviews, 2022. [Online]. Available: https://researchgate.net
[54] Abdulmuttaleb, N. A., M. Q. Mohammed, and O. A. Mohsein, "The impact of adipocytokines on thyroid function and obesity: A narrative review," Development, vol. 8, p. 9, 2024.
[55] P. Peng et al., "Emerging ELISA derived technologies for in vitro diagnostics," TrAC Trends in Analytical Chemistry, vol. 152, p. 116605, 2022. [Online]. Available: [HTML]
[56] M. S. Tabatabaei, R. Islam, and M. Ahmed, "Applications of gold nanoparticles in ELISA, PCR, and immuno-PCR assays: A review," Analytica Chimica Acta, 2021. [Online]. Available: [HTML]
[57] Y. Xiong et al., "Emerging strategies to enhance the sensitivity of competitive ELISA for detection of chemical contaminants in food samples," TrAC Trends in Analytical Chemistry, vol. 126, p. 115861, 2020. [Online]. Available: [HTML]
[58] R. Minic and I. Zivkovic, "Optimization, validation and standardization of ELISA," Norovirus, 2020. [Online]. Available: https://intechopen.com
[59] Y. Ju and K. Y. Tam, "Pathological mechanisms and therapeutic strategies for Alzheimer's disease," Neural Regeneration Research, 2022. [Online]. Available: https://lww.com
[60] E. Passeri et al., "Alzheimer’s disease: treatment strategies and their limitations," International Journal of Molecular Sciences, vol. 23, no. 22, p. 13954, 2022. [Online]. Available: https://mdpi.com
[61] M. Vaz and S. Silvestre, "Alzheimer's disease: Recent treatment strategies," European Journal of Pharmacology, 2020. [Online]. Available: [HTML]
[62] Y. Zhang, H. Chen, R. Li, K. Sterling, and W. Song, "Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future," Signal Transduction and Targeted Therapy, vol. 8, no. 1, p. 248, 2023. [Online]. Available: nature.com.
[63] S. Ghosh, R. Ali, and S. Verma, "Aβ-oligomers: A potential therapeutic target for Alzheimer's disease," International Journal of Biological Macromolecules, vol. 239, p. 124231, 2023. [Online]. Available: [HTML].
[64] T. Pardo-Moreno, A. González-Acedo, A. Rivas-Domínguez, V. García-Morales, F. J. García-Cozar, J. J. Ramos-Rodríguez, and L. Melguizo-Rodríguez, "Therapeutic approach to Alzheimer’s disease: current treatments and new perspectives," Pharmaceutics, vol. 14, no. 6, p. 1117, 2022. [Online]. Available: mdpi.com.
[65] D. Jeremic, L. Jiménez-Díaz, and J. D. Navarro-López, "Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review," Ageing Research Reviews, 2021. [Online]. Available: sciencedirect.com.
[66] Y. Zhang, K. M. Wu, L. Yang, Q. Dong, and J. T. Yu, "Tauopathies: new perspectives and challenges," Molecular Neurodegeneration, 2022. [Online]. Available: springer.com.
[67] K. B. E. Moore, T. J. Hung, and J. S. Fortin, "Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies," Drug Discovery Today, 2023. [Online]. Available: sciencedirect.com.
[68] E. Mulroy, Z. Jaunmuktane, B. Balint, R. Erro, A. Latorre, and K. P. Bhatia, "Some new and unexpected tauopathies in movement disorders," Movement Disorders Clinical Practice, vol. 7, no. 6, pp. 616, 2020. [Online]. Available: nih.gov.
[69] S. R. Saroja, A. Sharma, P. R. Hof, and A. C. Pereira, "Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease," Alzheimer's & Dementia, vol. 18, no. 9, pp. 1602-1615, 2022. [Online]. Available: nih.gov.
[70] D. V. Agoston and A. Helmy, "Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside," International Journal of Molecular Sciences, 2023. [Online]. Available: mdpi.com.
[71] H. Zetterberg, "Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature," Alzheimer's & Dementia, 2022. [Online]. Available: nih.gov.
[72] N. K. Tran, S. Albahra, L. May, S. Waldman, S. Crabtree, S. Bainbridge, and H. Rashidi, "Evolving applications of artificial intelligence and machine learning in infectious diseases testing," Clinical Chemistry, vol. 68, no. 1, pp. 125-133, 2022. [Online]. Available: nih.gov.
[73] M. J. Iqbal, Z. Javed, H. Sadia, I. A. Qureshi, A. Irshad, R. Ahmed, et al., "Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future," Cancer Cell International, vol. 21, no. 1, p. 270, 2021. [Online]. Available: springer.com.
[74] D. S. Herman, D. D. Rhoads, W. L. Schulz, and T. J. Durant, "Artificial intelligence and mapping a new direction in laboratory medicine: a review," Clinical Chemistry, vol. 67, no. 11, pp. 1466-1482, 2021. [Online]. Available: [HTML].
[75] A. Cano, P. Turowski, M. Ettcheto, J. T. Duskey, G. Tosi, E. Sánchez-López, et al., "Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges," Journal of Nanobiotechnology, vol. 19, no. 1, p. 122, 2021. [Online]. Available: springer.com.
[76] N. Puranik, D. Yadav, and M. Song, "Advancements in the Application of Nanomedicine in Alzheimer's Disease: A Therapeutic Perspective," International Journal of Molecular Sciences, 2023. [Online]. Available: mdpi.com.
[77] C. Cáceres, B. Heusser, A. Garnham, and E. Moczko, "The major hypotheses of Alzheimer's disease: related nanotechnology-based approaches for its diagnosis and treatment," Cells, 2023. [Online]. Available: mdpi.com.
[78] H. Zetterberg and K. Blennow, "Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics," Molecular Neurodegeneration, 2021. [Online]. Available: springer.com.
[79] M. M. Budelier and R. J. Bateman, "Biomarkers of Alzheimer disease," The Journal of Applied Laboratory Medicine, vol. 5, no. 1, pp. 194-208, 2020. [Online]. Available: nih.gov.
[80] O. Hansson, R. M. Edelmayer, A. L. Boxer, M. C. Carrillo, M. M. Mielke, G. D. Rabinovici, et al., "The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease," Alzheimer's & Dementia, vol. 18, no. 12, pp. 2669-2686, 2022. [Online]. Available: wiley.com.
[81] E. Ausó, V. Gómez-Vicente, and G. Esquiva, "Biomarkers for Alzheimer's disease early diagnosis," Journal of Personalized Medicine, 2020. [Online]. Available: mdpi.com.
[82] Y. A. R. Mahaman, K. S. Embaye, F. Huang, L. Li, F. Zhu, J. Z. Wang, et al., "Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention," Ageing Research Reviews, vol. 74, p. 101544, 2022. [Online]. Available: [HTML].
[83] T. O. Klyucherev, P. Olszewski, A. A. Shalimova, V. N. Chubarev, V. V. Tarasov, M. M. Attwood, et al., "Advances in the development of new biomarkers for Alzheimer’s disease," Translational Neurodegeneration, vol. 11, no. 1, p. 25, 2022. [Online]. Available: springer.com.
[84] M. N. Sabbagh, M. Boada, S. Borson, M. Chilukuri, P. M. Doraiswamy, B. Dubois, et al., "Rationale for early diagnosis of mild cognitive impairment (MCI) supported by emerging digital technologies," The Journal of Prevention of Alzheimer's Disease, vol. 7, pp. 158-164, 2020. [Online]. Available: springer.com.
[85] F. Öhman, J. Hassenstab, D. Berron, M. Schöll, and K. V. Papp, "Current advances in digital cognitive assessment for preclinical Alzheimer's disease," Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol. 13, no. 1, p. e12217, 2021. [Online]. Available: wiley.com.
[86] A. P. Porsteinsson, R. S. Isaacson, S. Knox, M. N. Sabbagh, and I. Rubino, "Diagnosis of early Alzheimer’s disease: clinical practice in 2021," The Journal of Prevention of Alzheimer's Disease, vol. 8, pp. 371-386, 2021. [Online]. Available: springer.com.
[87] D. M. Cammisuli, G. Cipriani, and G. Castelnuovo, "Technological solutions for diagnosis, management and treatment of Alzheimer’s disease-related symptoms: A structured review of the recent scientific literature," International Journal of Environmental Research and Public Health, vol. 19, no. 5, p. 3122, 2022. [Online]. Available: mdpi.com.
[88] R. N. Rosenberg, "Translational research on the way to effective therapy for Alzheimer disease," Archives of General Psychiatry, vol. 62, no. 11, pp. 1186-1192, 2005.
[89] R. Tarawneh and D. M. Holtzman, "Biomarkers in translational research of Alzheimer’s disease," Neuropharmacology, vol. 59, no. 4-5, pp. 310-322, 2010.
[90] L.-K. Huang, S.-P. Chao, and C.-J. Hu, "Clinical trials of new drugs for Alzheimer disease," Journal of Biomedical Science, vol. 27, p. 1-13, 2020.
[91] J. Cummings, "Lessons learned from Alzheimer disease: clinical trials with negative outcomes," Clinical and Translational Science, vol. 11, no. 2, p. 147, 2017.
[92] G. Di Fede, et al., "Translational research in Alzheimer’s and Prion diseases," Journal of Alzheimer’s Disease, vol. 62, no. 3, pp. 1247-1259, 2018.
[2] M. Heron, "Deaths: leading causes for 2019," cdc.gov, 2021. [Online]. Available: https://cdc.gov
[3] C. S. Liang et al., "Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis," The Lancet Healthy Longevity, vol. 2, no. 8, pp. e479-e488, 2021. [Online]. Available: https://thelancet.com
[4] M. B. Abubakar et al., "Alzheimer’s disease: an update and insights into pathophysiology," Frontiers in Aging Neuroscience, vol. 14, p. 742408, 2022. [Online]. Available: https://frontiersin.org
[5] Rahman, Z. Banu, R. Rani, and R. Mehdiya, "Unravelling Alzheimer’s disease: Insights into pathophysiology, etiology, diagnostic approaches, and the promise of aducanumab, lecanemab, and donanemab," Journal of Phytonanotechnology and Pharmaceutical Sciences, vol. 4, no. 3, pp. 1-10, 2024. [Online]. Available: https://researchgate.net
[6] Crestini et al., "Prions and neurodegenerative diseases: a focus on Alzheimer’s disease," Journal of Alzheimer's Disease, vol. 85, no. 2, pp. 503-518, 2022. [Online]. Available: https://escholarship.org
[7] N. Pathak et al., "Neurodegenerative disorders of Alzheimer, Parkinsonism, amyotrophic lateral sclerosis and multiple sclerosis: an early diagnostic approach for precision treatment," Metabolic Brain Disease, pp. 1-38, 2021. [Online]. Available: [HTML].
[8] V. Litvinenko and V. Y. Lobzin, "On a New Paradigm of the Development of Neurodegenerative Diseases by the Example of Alzheimer's Disease and Parkinson's Disease," Advances in Gerontology, 2022. [Online]. Available: https://springer.com
[9] X. Zhao et al., "Mesenchymal stem cell therapies for Alzheimer's disease: preclinical studies," Metabolic Brain Disease, 2021. [Online]. Available: [HTML].
[10] A. King, I. Bodi, and C. Troakes, "The neuropathological diagnosis of Alzheimer's disease—the challenges of pathological mimics and concomitant pathology," Brain Sciences, 2020. [Online]. Available: https://mdpi.com
[11] F. J. Hart de Ruyter et al., "Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases," Acta Neuropathologica, vol. 148, no. 1, p. 24, 2024. [Online]. Available: https://springer.com
[12] P. Sánchez-Juan et al., "Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles," Brain, vol. 147, no. 5, pp. 1667-1679, 2024. [Online]. Available: https://oup.com
[13] A. D. Henriques et al., "Genome-wide profiling and predicted significance of post-mortem brain microRNA in Alzheimer’s disease," Mechanisms of Ageing and Development, vol. 191, p. 111352, 2020. [Online]. Available: [HTML].
[14] X. Yin et al., "The role of amyloid-beta and tau in the early pathogenesis of Alzheimer’s Disease," Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, vol. 27, p. e933084-1, 2021. [Online]. Available: https://nih.gov
[15] H. Zhang et al., "Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease," International Journal of Biological Sciences, vol. 17, no. 9, p. 2181, 2021. [Online]. Available: https://nih.gov
[16] A. R. Roda et al., "Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease," Neural Regeneration Research, vol. 17, no. 8, pp. 1666-1674, 2022. [Online]. Available: https://lww.com
[17] S. Muralidar et al., "Role of tau protein in Alzheimer's disease: The prime pathological player," International Journal of Biological Macromolecules, vol. 163, pp. 1599-1617, 2020. [Online]. Available: https://academia.edu
[18] Lateef, D., Nasser, N., and Mohsein, O., "The relationships between Apelin, Vaspin and thyroid hormone levels in obese diabetic and non-diabetic women," Journal of Experimental and Clinical Medicine, vol. 41, no. 2, pp. 239-245, 2024.
[19] Y. H. Guan et al., "The role of microglia in Alzheimer's disease and progress of treatment," Ibrain, vol. 8, no. 1, pp. 37-47, 2022. [Online]. Available: https://wiley.com
[20] Y. Cai et al., "Microglia in the neuroinflammatory pathogenesis of Alzheimer's disease and related therapeutic targets," Frontiers in Immunology, 2022. [Online]. Available: https://frontiersin.org
[21] Z. Du, M. Li, J. Ren, and X. Qu, "Current strategies for modulating Aβ aggregation with multifunctional agents," Accounts of Chemical Research, 2021. [Online]. Available: [HTML].
[22] Q. Shi, R. A. Gutierrez, and M. A. Bhat, "Microglia, Trem2, and Neurodegeneration," The Neuroscientist, 2024. [Online]. Available: https://sagepub.com
[23] Faisal, A. N., Abbas, A. M., and Mohsein, O. A., "Histological and cytokine-based biomarkers in the early diagnosis of cancer," Indonesian Journal on Health Science and Medicine, vol. 2, no. 2, pp. 10-21070, 2025.
[24] M. Abbas, "Potential role of nanoparticles in treating the accumulation of amyloid-beta peptide in Alzheimer's patients," Polymers, 2021. [Online]. Available: https://mdpi.com
[25] J. Gupta, R. Gupta, and P. Sharma, "Alzheimer’s Disease: Role of Amyloid-β Peptide in the Pathogenesis of Neurodisorder," European Journal of Molecular & Clinical Medicine, vol. 9, no. 7, pp. 7282-7290, 2022. [Online]. Available: https://researchgate.net
[26] M. Inyushin, A. Zayas-Santiago, L. Rojas, and L. Kucheryavykh, "On the role of platelet-generated amyloid beta peptides in certain amyloidosis health complications," Frontiers in Immunology, vol. 11, p. 571083, 2020. [Online]. Available: https://frontiersin.org
[27] M. K. Rasmussen, H. Mestre, and M. Nedergaard, "Fluid transport in the brain," Physiological Reviews, vol. 102, no. 2, pp. 1025-1151, 2022. [Online]. Available: https://physiology.org
[28] A. Al-Mekhlafi et al., "Elevated free phosphatidylcholine levels in cerebrospinal fluid distinguish bacterial from viral CNS infections," Cells, vol. 10, no. 5, p. 1115, 2021. [Online]. Available: https://mdpi.com
[29] Adnan, A., Farhan, Z. M., and Mohsein, O. A., "Understanding the link between diabetes mellitus and fatty liver disease: A narrative review," Int. J. Chem. Stud., vol. 12, no. 4, pp. 40-48, 2024.
[30] M. Blomqvist, H. Zetterberg, K. Blennow, and J. E. Månsson, "Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration," Molecular and Cellular Neuroscience, vol. 116, p. 103670, 2021. [Online]. Available: https://sciencedirect.com
[31] A. Varesi et al., "Blood-based biomarkers for Alzheimer’s disease diagnosis and progression: an overview," Cells, vol. 11, no. 8, p. 1367, 2022. [Online]. Available: https://mdpi.com
[32] S. Mankhong et al., "Development of Alzheimer’s disease biomarkers: From CSF-to blood-based biomarkers," Biomedicines, vol. 10, no. 4, p. 850, 2022. [Online]. Available: https://mdpi.com
[33] S. P. Padala and P. A. Newhouse, "Blood-based biomarkers in Alzheimer's disease: A mini-review," Metabolic Brain Disease, 2023. [Online]. Available: https://nih.gov
[34] Abdulmuttaleb, N. A., Mohammed, M. Q., and Mohsein, O. A., "Exploring the connection between inflammatory cytokines, hypertension, and diabetes in angina patients," Cytokines, vol. 14, no. 15, p. 16, 2024.
[35] S. Lista et al., "A critical appraisal of blood-based biomarkers for Alzheimer’s disease," Ageing Research Reviews, p. 102290, 2024. [Online]. Available: [HTML].
[36] H. Hampel et al., "The amyloid-β pathway in Alzheimer’s disease," Molecular Psychiatry, vol. 26, no. 10, pp. 5481-5503, 2021. [Online]. Available: https://nature.com
[37] M. Seuma, B. Lehner, and B. Bolognesi, "An atlas of amyloid aggregation: the impact of substitutions, insertions, deletions and truncations on amyloid beta fibril nucleation," Nature Communications, 2022. [Online]. Available: https://nature.com
[38] Abbas, A. M., Shewael, I. H., and Mohsein, O. A., "Lipoprotein ratios as biomarkers for assessing chronic atherosclerosis progression," Academia Open, vol. 10, no. 1, pp. 10-21070, 2025.
[39] R. Fernández-Calle et al., "APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases," Molecular Neurodegeneration, vol. 17, no. 1, p. 62, 2022. [Online]. Available: https://springer.com
[40] X. Zhou, A. K. Y. Fu, and N. Y. Ip, "APOE signaling in neurodegenerative diseases: an integrative approach targeting APOE coding and noncoding variants for disease intervention," Current Opinion in Neurobiology, 2021. [Online]. Available: https://sciencedirect.com
[41] S. Parhizkar and D. M. Holtzman, "APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease," Seminars in Immunology, 2022. [Online]. Available: https://sciencedirect.com
[42] J. Goldman et al., "Predictive testing for neurodegenerative diseases in the age of next-generation sequencing," Journal of Genetic Counseling, vol. 30, no. 2, pp. 553-562, 2021. [Online]. Available: https://wiley.com
[43] M. Zhao et al., "A study of the SORL1 gene in the pathogenesis of late-onset Alzheimer’s disease by affecting the expression of BDNF," Research Square, 2021. [Online]. Available: https://researchsquare.com
[44] K. Barthelson et al., "… analysis reveals subtle effects on mitochondrial function and iron homeostasis of mutations in the SORL1 gene implicated in early onset familial Alzheimer's disease," Molecular Brain, 2020. [Online]. Available: https://springer.com
[45] Abbas, Z. K., et al., "Immunological biomarkers and their role in the diagnosis and prognosis of leishmaniasis: A case–control study," Tropical Parasitology, vol. 15, no. 1, pp. 33-41, 2025.
[46] C. Y. Chen et al., "Endophenotypic effects of the SORL1 variant rs2298813 on regional brain volume in patients with late-onset Alzheimer’s disease," Frontiers in Aging Neuroscience, vol. 14, p. 885090, 2022. [Online]. Available: https://frontiersin.org
[47] M. M. Rahman and C. Lendel, "Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology," Molecular Neurodegeneration, 2021. [Online]. Available: https://springer.com
[48] S. Srivastava, R. Ahmad, and S. K. Khare, "Alzheimer’s disease and its treatment by different approaches: A review," European Journal of Medicinal Chemistry, vol. 216, p. 113320, 2021. [Online]. Available: [HTML]
[49] U. Ganguly et al., "Oxidative stress, neuroinflammation, and NADPH oxidase: implications in the pathogenesis and treatment of Alzheimer’s disease," Oxidative Medicine and Cellular Longevity, vol. 2021, p. 7086512, 2021. [Online]. Available: https://wiley.com
[50] K. D. Anapindi et al., "Mass spectrometry approaches empowering neuropeptide discovery and therapeutics," Pharmacological Reviews, vol. 74, no. 3, pp. 662-679, 2022. [Online]. Available: https://nih.gov
[51] C. S. Sauer et al., "Developing mass spectrometry for the quantitative analysis of neuropeptides," Expert Review of Proteomics, vol. 18, no. 7, pp. 607-621, 2021. [Online]. Available: https://nih.gov
[52] J. Li and X. Zhan, "Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas," Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, vol. 1869, no. 3, p. 140584, 2021. [Online]. Available: [HTML]
[53] N. Li, D. M. Desiderio, and X. Zhan, "The use of mass spectrometry in a proteome-centered multiomics study of human pituitary adenomas," Mass Spectrometry Reviews, 2022. [Online]. Available: https://researchgate.net
[54] Abdulmuttaleb, N. A., M. Q. Mohammed, and O. A. Mohsein, "The impact of adipocytokines on thyroid function and obesity: A narrative review," Development, vol. 8, p. 9, 2024.
[55] P. Peng et al., "Emerging ELISA derived technologies for in vitro diagnostics," TrAC Trends in Analytical Chemistry, vol. 152, p. 116605, 2022. [Online]. Available: [HTML]
[56] M. S. Tabatabaei, R. Islam, and M. Ahmed, "Applications of gold nanoparticles in ELISA, PCR, and immuno-PCR assays: A review," Analytica Chimica Acta, 2021. [Online]. Available: [HTML]
[57] Y. Xiong et al., "Emerging strategies to enhance the sensitivity of competitive ELISA for detection of chemical contaminants in food samples," TrAC Trends in Analytical Chemistry, vol. 126, p. 115861, 2020. [Online]. Available: [HTML]
[58] R. Minic and I. Zivkovic, "Optimization, validation and standardization of ELISA," Norovirus, 2020. [Online]. Available: https://intechopen.com
[59] Y. Ju and K. Y. Tam, "Pathological mechanisms and therapeutic strategies for Alzheimer's disease," Neural Regeneration Research, 2022. [Online]. Available: https://lww.com
[60] E. Passeri et al., "Alzheimer’s disease: treatment strategies and their limitations," International Journal of Molecular Sciences, vol. 23, no. 22, p. 13954, 2022. [Online]. Available: https://mdpi.com
[61] M. Vaz and S. Silvestre, "Alzheimer's disease: Recent treatment strategies," European Journal of Pharmacology, 2020. [Online]. Available: [HTML]
[62] Y. Zhang, H. Chen, R. Li, K. Sterling, and W. Song, "Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future," Signal Transduction and Targeted Therapy, vol. 8, no. 1, p. 248, 2023. [Online]. Available: nature.com.
[63] S. Ghosh, R. Ali, and S. Verma, "Aβ-oligomers: A potential therapeutic target for Alzheimer's disease," International Journal of Biological Macromolecules, vol. 239, p. 124231, 2023. [Online]. Available: [HTML].
[64] T. Pardo-Moreno, A. González-Acedo, A. Rivas-Domínguez, V. García-Morales, F. J. García-Cozar, J. J. Ramos-Rodríguez, and L. Melguizo-Rodríguez, "Therapeutic approach to Alzheimer’s disease: current treatments and new perspectives," Pharmaceutics, vol. 14, no. 6, p. 1117, 2022. [Online]. Available: mdpi.com.
[65] D. Jeremic, L. Jiménez-Díaz, and J. D. Navarro-López, "Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review," Ageing Research Reviews, 2021. [Online]. Available: sciencedirect.com.
[66] Y. Zhang, K. M. Wu, L. Yang, Q. Dong, and J. T. Yu, "Tauopathies: new perspectives and challenges," Molecular Neurodegeneration, 2022. [Online]. Available: springer.com.
[67] K. B. E. Moore, T. J. Hung, and J. S. Fortin, "Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies," Drug Discovery Today, 2023. [Online]. Available: sciencedirect.com.
[68] E. Mulroy, Z. Jaunmuktane, B. Balint, R. Erro, A. Latorre, and K. P. Bhatia, "Some new and unexpected tauopathies in movement disorders," Movement Disorders Clinical Practice, vol. 7, no. 6, pp. 616, 2020. [Online]. Available: nih.gov.
[69] S. R. Saroja, A. Sharma, P. R. Hof, and A. C. Pereira, "Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease," Alzheimer's & Dementia, vol. 18, no. 9, pp. 1602-1615, 2022. [Online]. Available: nih.gov.
[70] D. V. Agoston and A. Helmy, "Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside," International Journal of Molecular Sciences, 2023. [Online]. Available: mdpi.com.
[71] H. Zetterberg, "Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature," Alzheimer's & Dementia, 2022. [Online]. Available: nih.gov.
[72] N. K. Tran, S. Albahra, L. May, S. Waldman, S. Crabtree, S. Bainbridge, and H. Rashidi, "Evolving applications of artificial intelligence and machine learning in infectious diseases testing," Clinical Chemistry, vol. 68, no. 1, pp. 125-133, 2022. [Online]. Available: nih.gov.
[73] M. J. Iqbal, Z. Javed, H. Sadia, I. A. Qureshi, A. Irshad, R. Ahmed, et al., "Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future," Cancer Cell International, vol. 21, no. 1, p. 270, 2021. [Online]. Available: springer.com.
[74] D. S. Herman, D. D. Rhoads, W. L. Schulz, and T. J. Durant, "Artificial intelligence and mapping a new direction in laboratory medicine: a review," Clinical Chemistry, vol. 67, no. 11, pp. 1466-1482, 2021. [Online]. Available: [HTML].
[75] A. Cano, P. Turowski, M. Ettcheto, J. T. Duskey, G. Tosi, E. Sánchez-López, et al., "Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges," Journal of Nanobiotechnology, vol. 19, no. 1, p. 122, 2021. [Online]. Available: springer.com.
[76] N. Puranik, D. Yadav, and M. Song, "Advancements in the Application of Nanomedicine in Alzheimer's Disease: A Therapeutic Perspective," International Journal of Molecular Sciences, 2023. [Online]. Available: mdpi.com.
[77] C. Cáceres, B. Heusser, A. Garnham, and E. Moczko, "The major hypotheses of Alzheimer's disease: related nanotechnology-based approaches for its diagnosis and treatment," Cells, 2023. [Online]. Available: mdpi.com.
[78] H. Zetterberg and K. Blennow, "Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics," Molecular Neurodegeneration, 2021. [Online]. Available: springer.com.
[79] M. M. Budelier and R. J. Bateman, "Biomarkers of Alzheimer disease," The Journal of Applied Laboratory Medicine, vol. 5, no. 1, pp. 194-208, 2020. [Online]. Available: nih.gov.
[80] O. Hansson, R. M. Edelmayer, A. L. Boxer, M. C. Carrillo, M. M. Mielke, G. D. Rabinovici, et al., "The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease," Alzheimer's & Dementia, vol. 18, no. 12, pp. 2669-2686, 2022. [Online]. Available: wiley.com.
[81] E. Ausó, V. Gómez-Vicente, and G. Esquiva, "Biomarkers for Alzheimer's disease early diagnosis," Journal of Personalized Medicine, 2020. [Online]. Available: mdpi.com.
[82] Y. A. R. Mahaman, K. S. Embaye, F. Huang, L. Li, F. Zhu, J. Z. Wang, et al., "Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention," Ageing Research Reviews, vol. 74, p. 101544, 2022. [Online]. Available: [HTML].
[83] T. O. Klyucherev, P. Olszewski, A. A. Shalimova, V. N. Chubarev, V. V. Tarasov, M. M. Attwood, et al., "Advances in the development of new biomarkers for Alzheimer’s disease," Translational Neurodegeneration, vol. 11, no. 1, p. 25, 2022. [Online]. Available: springer.com.
[84] M. N. Sabbagh, M. Boada, S. Borson, M. Chilukuri, P. M. Doraiswamy, B. Dubois, et al., "Rationale for early diagnosis of mild cognitive impairment (MCI) supported by emerging digital technologies," The Journal of Prevention of Alzheimer's Disease, vol. 7, pp. 158-164, 2020. [Online]. Available: springer.com.
[85] F. Öhman, J. Hassenstab, D. Berron, M. Schöll, and K. V. Papp, "Current advances in digital cognitive assessment for preclinical Alzheimer's disease," Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol. 13, no. 1, p. e12217, 2021. [Online]. Available: wiley.com.
[86] A. P. Porsteinsson, R. S. Isaacson, S. Knox, M. N. Sabbagh, and I. Rubino, "Diagnosis of early Alzheimer’s disease: clinical practice in 2021," The Journal of Prevention of Alzheimer's Disease, vol. 8, pp. 371-386, 2021. [Online]. Available: springer.com.
[87] D. M. Cammisuli, G. Cipriani, and G. Castelnuovo, "Technological solutions for diagnosis, management and treatment of Alzheimer’s disease-related symptoms: A structured review of the recent scientific literature," International Journal of Environmental Research and Public Health, vol. 19, no. 5, p. 3122, 2022. [Online]. Available: mdpi.com.
[88] R. N. Rosenberg, "Translational research on the way to effective therapy for Alzheimer disease," Archives of General Psychiatry, vol. 62, no. 11, pp. 1186-1192, 2005.
[89] R. Tarawneh and D. M. Holtzman, "Biomarkers in translational research of Alzheimer’s disease," Neuropharmacology, vol. 59, no. 4-5, pp. 310-322, 2010.
[90] L.-K. Huang, S.-P. Chao, and C.-J. Hu, "Clinical trials of new drugs for Alzheimer disease," Journal of Biomedical Science, vol. 27, p. 1-13, 2020.
[91] J. Cummings, "Lessons learned from Alzheimer disease: clinical trials with negative outcomes," Clinical and Translational Science, vol. 11, no. 2, p. 147, 2017.
[92] G. Di Fede, et al., "Translational research in Alzheimer’s and Prion diseases," Journal of Alzheimer’s Disease, vol. 62, no. 3, pp. 1247-1259, 2018.
Published
2025-04-22
How to Cite
Abdullah Kareem, S., Abd, M. Y., Neamah Hammood, M., & Adnan Naser , M. (2025). Understanding the Biochemical Basis of Alzheimer’s Disease: A Clinical Chemistry Approach. Central Asian Journal of Medical and Natural Science, 6(3), 938-953. https://doi.org/10.17605/cajmns.v6i3.2789
Section
Articles
Copyright (c) 2025 Sada Abdullah Kareem, Mena Y Abd, Mohammed Neamah Hammood, Maryam Adnan Naser
This work is licensed under a Creative Commons Attribution 4.0 International License.
